中国医科大学学报

中国医科大学学报
  • 中文核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
  • BA、CA收录

中国医科大学学报 ›› 2018, Vol. 47 ›› Issue (10): 905-908,913.doi: 10.12007/j.issn.0258-4646.2018.10.009

• 论著 • 上一篇    下一篇

小干扰RNA下调PLK1表达对食管腺癌细胞肿瘤生物学行为的影响

杜媛鲲1, 赵永波2, 米源2, 陈阁2, 廖海江2, 王雷2   

  1. 1. 河北医科大学期刊社, 石家庄 050017;
    2. 河北医科大学第四医院胸心外科, 石家庄 050011
  • 收稿日期:2017-12-26 出版日期:2018-10-30 发布日期:2018-09-30
  • 通讯作者: 王雷 E-mail:yuankundu@163.com
  • 作者简介:杜媛鲲(1980-),女,副编审,硕士.
  • 基金资助:
    河北省科技厅科技攻关计划(132077127D);河北省卫计委医学重点科研基金(20160177)

Silencing PLK1 with Small Interfering RNA Modulates the Biologic Behavior of Esophageal Adenocarcinoma

DU Yuankun1, ZHAO Yongbo2, MI Yuan2, CHEN Ge2, LIAO Haijiang2, WANG Lei2   

  1. 1. Agency of Periodicals, Hebei Medical University, Shijiazhuang 050017, China;
    2. Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
  • Received:2017-12-26 Online:2018-10-30 Published:2018-09-30

摘要: 目的 研究polo样激酶1(PLK1)表达下调对食管腺癌OE33细胞肿瘤生物学行为的影响,并探讨其相关的分子机制。方法 将PLK1小干扰RNA(siRNA)和空白对照siRNA转染OE33细胞48 h,实时荧光定量PCR法检测OE33细胞PLK1 mRNA表达水平;采用Western blotting检测OE33细胞中PLK1、E-cadherin、N-cadherin和C-myc蛋白的表达水平;流式细胞术检测OE33细胞周期分布;Transwell实验检测OE33细胞侵袭能力的改变。结果 采用PLK1 siRNA抑制PLK1 mRNA和蛋白表达后可以下调C-myc蛋白表达,将细胞周期阻滞在G2/M期;同时可以通过减少N-cadherin蛋白表达,上调E-cadherin蛋白表达,降低细胞的侵袭能力,与空白对照siRNA组比较,差异均有统计学意义(P < 0.01)。结论 PLK1在食管腺癌的生长转移中具有重要作用,敲除PLK1基因表达可抑制细胞有丝分裂和侵袭能力。

关键词: RNA干扰, 食管腺癌, polo样激酶1, 细胞周期, 上皮-间质转化

Abstract: Objective To explore the effect of downregulation of polo-like kinase 1 (PLK1)expression on the growth and invasion of esophageal adenocarcinoma OE33 cells and the underlying molecular mechanism. Methods PLK1 small interfering RNA (siRNA)and negative control siRNA were each transfected into OE33 cells for 48 h. The expression of PLK1 mRNA was detected by real-time,fluorescence quantitative PCR. The expression of proteins PLK1,E-cadherin,N-cadherin,and C-myc were detected by Western blotting. The cell cycle was determined using flow cytometry. In addition,the invasive ability of the cells was detected by Transwell assay. Results Inhibition of PLK1 mRNA and protein expression by PLK1 siRNA downregulated the expression of C-myc and stopped the cell cycle in the G 2/M phase. At the same time,reduced expression of N-cadherin and upregulated expression of E-cadherin reduced the invasive ability of the cells in a statistically significant way,compared to control siRNA (P < 0.01). Conclusion PLK1 may play an orchestral role in the growth and invasion of esophageal adenocarcinoma. PLK1 knockdown can inhibit cell mitosis and invasion.

Key words: RNA interference, esophageal adenocarcinoma, polo-like kinase 1, cell cycle, epithelial-mesenchymal transition

中图分类号: 

  • R734.2
[1] PENNATHUR A,GIBSON MK,JOBE BA,et al. Oesophageal carcinoma[J]. Lancet,2013,381(9864):400-412. DOI:10.1016/S0140-6736(12)60643-6.
[2] FAN YJ,SONG X,LI JL,et al. Esophageal and gastric cardia cancers on 4238 Chinese patients residing in municipal and rural regions:a histopathological comparison during 24-year period[J]. World J Surg, 2008,32(9):1980-1988. DOI:10.1007/s00268-008-9674-x.
[3] CHEN L,LI J,FARAH E,et al. Cotargeting HSP90 and its client proteins for treatment of prostate cancer[J]. Mol Cancer Ther,2016, 15(9):2107-2118. DOI:10.1158/1535-7163.MCT-16-0241.
[4] MAO Y,XI L,LI Q,et al. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1[J]. Oncol Rep,2016,36(1):49-56. DOI:10.3892/or.2016.4820.
[5] OTSU H,ⅡMORI M,ANDO K,et al. Gastric cancer patients with high PLK1 expression and DNA aneuploidy correlate with poor prognosis[J]. Oncology,2016,91(1):31-40. DOI:10.1159/000445952.
[6] PANG X,LIU M. A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS[J]. Chin J Cancer,2016,35(1):92.
[7] CRAIG SN,WYATT MD,MCINES C. Current assessment of polo-like kinases as anti-tumor drug targets[J]. Expert Opin Drug Discov, 2014,9(7):773-789. DOI:10.1517/17460441.2014.918100.
[8] CAI XP,CHEN LD,SONG HB,et al. PLK1 promotes epithelial-mesenchymal transition and metastasis of gastric carcinoma cells[J]. Am J Transl Res,2016,8(10):4172-4183.
[9] GUTTERIDGE RE,NDIAYE MA,LIU X,et al. Plk1 inhibitors in cancer therapy:from laboratory to clinics[J]. Mol Cancer Ther,2016, 15(7):1427-1435. DOI:10.1158/1535-7163.MCT-15-0897.
[10] AMANI V,PRINCE EW,ALIMOVA I,et al. Polo-like kinase 1 as a potential therapeutic target in diffuse intrinsic pontine glioma[J]. BMC Cancer,2016,16:647. DOI:10.1186/s12885-016-2690-6.
[11] SONG LB,LI J,LIAO WT,et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells[J]. J Clin Invest,2009,119(12):3626-3636. DOI:10.1172/JCI39374.
[12] TAN J,LI Z,LEE PL,et al. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation,tumor-initiating cell activation,and resistance to mTOR-targeted therapy[J]. Cancer Discov, 2013,3(10):1156-1171. DOI:10.1158/2159-8290.CD-12-0595.
[13] LI H,YUE D,JIN JQ,et al. Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas[J]. Oncotarget,2016,7(49):80415-80425. DOI:10.18632/oncotarget.11246.
[14] ZHANG W,WU X,HU L,et al. Overexpression of human papillomavirus type 16 oncoproteins enhances epithelial-mesenchymal transition via STAT3 signaling pathway in non-small cell lung cancer cells[J]. Oncol Res,2016,25(5):843-852. DOI:10.3727/096504016X14813880882288.
[15] LIU F,GU LN,SHAN BE,et al. Biomarkers for EMT and MET in breast cancer:an update[J]. Oncol Lett,2016,12(6):4869-4876. DOI:10.3892/ol.2016.5369.
[1] 康伊, 张艳, 张伟. 转化生长因子β信号在内皮细胞中通过上调ULK1蛋白抑制细胞周期[J]. 中国医科大学学报, 2018, 47(9): 783-787.
[2] 李忠华, 李慧峰, 李晓蕾. 瞬时感受器电位香草酸受体3促进胶质瘤U251细胞系增殖和侵袭[J]. 中国医科大学学报, 2018, 47(5): 394-397.
[3] 彭华童, 吴文艺, 张丽婷, 林建清, 余艺煌, 吴春林, 黄种心, 邱建龙. SIRT1沉默对人甲状腺乳头状癌细胞株TPC-1生物学功能的影响[J]. 中国医科大学学报, 2018, 47(4): 321-328.
[4] 王雷, 杜媛鲲, 米源, 廖海江, 陈阁, 张耀中, 刘庆熠. Hedgehog/Gli和PI3K/AKT信号通路的串话促进胃癌AZ521细胞上皮-间质转化[J]. 中国医科大学学报, 2018, 47(2): 151-156.
[5] 季相禄,田峰,王斌,肖万安. 葛根素治疗急性脊髓缺血再灌注损伤大鼠的神经保护机制[J]. 中国医科大学学报, 2017, 46(4): 313-316.
[6] 刘立峰,潘玉涛,陈涤,李侠,刘养洲,普星宇,李增春. 褪黑素通过下调细胞周期蛋白及其激酶的表达抑制人骨肉瘤MG-63 细胞增殖[J]. 中国医科大学学报, 2017, 46(2): 131-135.
[7] 丁夏峰,胡申江. CDKN2A、CDKN2B、MEF2A、VEGF 基因表达与冠状动脉粥样硬化性心脏病发生的相关性[J]. 中国医科大学学报, 2016, 45(6): 550-553.
[8] 王雷,杜媛鲲,王林,米源,王娜. GANT61对食管鳞癌细胞上皮-间质转化作用的研究[J]. 中国医科大学学报, 2016, 45(3): 249-254.
[9] 吴晶洋,白艳洁,王稚英. 富血小板纤维蛋白和浓缩生长因子对施万细胞影响的比较[J]. 中国医科大学学报, 2016, 45(12): 1089-1093.
[10] 刘立峰,李侠,潘玉涛,陈涤,刘养洲,普星宇,王喆,李增春. 不同浓度褪黑素对人骨肉瘤 MG-63 细胞增殖的影响[J]. 中国医科大学学报, 2016, 45(11): 1017-1021.
[11] 王雷 ,杜媛鲲 ,刘庆熠 ,米源 ,廖海江 ,王娜 ,王林. siRNA 下调 Gli 基因表达对食管鳞癌 KYSE-30 细胞生物学行为的影响[J]. 中国医科大学学报, 2016, 45(10): 918-922.
[12] 单广夷,付成,陈昂,胡滨,毕缓. 雷帕霉素对膀胱癌5637细胞增殖及细胞周期的影响[J]. 中国医科大学学报, 2015, 44(3): 230-233.
[13] 宫琦玉,汲坤,张丽艳,王波,楚琪,张明璇. RNA干扰抑制乳腺癌MCF?7细胞鼠双微体?2基因表达及细胞增殖的实验研究[J]. 中国医科大学学报, 2014, 43(10): 892-896.
[14] 孙倩,孙磊,金镇,范杰慧,息小雪. RNA干扰技术抑制SHBG基因表达对滋养细胞凋亡的影响[J]. 中国医科大学学报, 2013, 42(8): 689-692.
[15] 祁馨卉,崔慧霞,马楠,姜又红. GPC3基因重组慢病毒载体的构建及其在肝癌细胞中的表达[J]. 中国医科大学学报, 2013, 42(8): 726-729.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!

中国医科大学学报版权所有©2018

未经允许,严禁擅自转载本站图文资料

地址:中国 沈阳市沈北新区蒲河路77号 110122

辽ICP备05014850

JOURNAL OF CHINA MEDICAL UNIVERSITY

ADDRESS: NO.77 PUHE ROAD

SHENYANG NORTH NEW AREA, SHENYANG

LIAONING PROVINCE, P.R. CHINA